Navigation Links
NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
Date:7/1/2010

NEW YORK, July 1 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has appointed Roberto Bolli, M.D., to its Scientific Advisory Board. Dr. Bolli has produced an immense body of stem-cell research, including work emphasizing the ability of very small embryonic-like stem cells (VSELs) to regenerate and repair after myocardial infarction. He has received numerous awards and honors, produced over 300 peer-reviewed publications and lectured various audiences on topics related to his cardiovascular research, which has spanned three decades.

Dr. Bolli currently serves as Chief of the Division of Cardiology at the University of Louisville and is Director at the school's Institute of Molecular Cardiology. He also has been named Executive Vice Chairman of University of Louisville's Department of Medicine. He holds the Jewish Hospital Distinguished Chair in Cardiology and has pioneered, developed and led research programs from the ground up at both Baylor University and the University of Louisville.

Wayne A. Marasco, M.D., Ph.D., chair of NeoStem's Scientific Advisory Board, said, "We are extremely pleased to have Dr. Bolli join our advisory team. His in-depth understanding of the intricacies of VSELs and their potential to regenerate damaged heart tissue compliments well our goal of commercializing VSEL(TM) technology to improve the lives of the multitudes of heart failure sufferers in the US and China."

Dr. Bolli followed, "I am excited to join the Scientific Advisory Board of an innovative, forward-looking company like NeoStem and be part of the team of thought leaders to develop VSEL(TM) applications for cardiovascular disease. Not only has the Company put together a promising base of technology for stem cell treatment in orthopaedics, skin rejuvenation and cosmetics but it is beginning to partner with experts in other areas to facilitate meaningful R&D. This should encourage people to collect, process and store their stem cells through NeoStem's existing network in anticipation of a variety of future personalized medicine applications."

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL(TM) Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: rsmith@neostem.com
     Web:   http://www.neostem.com

    CCG Investor Relations, Inc.
     Kalle Ahl, Account Manager
     Phone: +1-646-833-3417
     Email: kalle.ahl@ccgir.com
     Web:   http://www.ccgirasia.com

    Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
2. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
3. NeoStem Announces Warrant Exercise by Principal Shareholder
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
8. PharmMDs Brad Tice to Receive Distinguished Achievement Award
9. Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award
10. Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer
11. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):